{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T21:55:01Z","timestamp":1770501301327,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2003,4,1]],"date-time":"2003-04-01T00:00:00Z","timestamp":1049155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2003,4]]},"DOI":"10.1053\/sonc.2003.50057","type":"journal-article","created":{"date-parts":[[2003,4,28]],"date-time":"2003-04-28T19:53:00Z","timestamp":1051559580000},"page":"253-257","source":"Crossref","is-referenced-by-count":53,"title":["CD22 as a target of passive immunotherapy"],"prefix":"10.1053","volume":"30","author":[{"given":"Alessandra","family":"Cesano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urte","family":"Gayko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/sonc.2003.50057_bib1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0952-7915(95)80110-3","article-title":"CD23 and B-cell activation","volume":"7","author":"Bonnefoy","year":"1995","journal-title":"Curr Opin Immunol"},{"key":"10.1053\/sonc.2003.50057_bib2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/366421a0","article-title":"The human IgE network","volume":"366","author":"Sutton","year":"1993","journal-title":"Nature"},{"key":"10.1053\/sonc.2003.50057_bib3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1600-065X.1995.tb00094.x","article-title":"Regulation of IgE synthesis. Lessons from the study of IgE transgenic and CD23-deficient mice","volume":"148","author":"Lamers","year":"1995","journal-title":"Immunol Rev"},{"key":"10.1053\/sonc.2003.50057_bib4","doi-asserted-by":"crossref","first-page":"7295","DOI":"10.1093\/nar\/15.18.7295","article-title":"Molecular structure of the gene and the 5\u2032-flanking region of the human lymphocyte immunoglobulin E receptor","volume":"15","author":"Suter","year":"1987","journal-title":"Nucleic Acids Res"},{"key":"10.1053\/sonc.2003.50057_bib5","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1084\/jem.182.5.1537","article-title":"A major house dust mite allergen disrupts the immunoglobulin E network by selectively cleaving CD23: Innate protection by antiproteases","volume":"182","author":"Hewitt","year":"1995","journal-title":"J Exp Med"},{"key":"10.1053\/sonc.2003.50057_bib6","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1084\/jem.181.4.1581","article-title":"Identification of the ligand-binding domains of CD22, a member of the immunoglobulin superfamily that uniquely binds a sialic acid-dependent ligand","volume":"181","author":"Engel","year":"1995","journal-title":"J Exp Med"},{"key":"10.1053\/sonc.2003.50057_bib7","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/eji.1830250616","article-title":"Phosphotyrosine-dependent association between CD22 and protein tyrosine phosphatase 1C","volume":"25","author":"Campbell","year":"1995","journal-title":"Eur J Immunol"},{"key":"10.1053\/sonc.2003.50057_bib8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1126\/science.7618087","article-title":"A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP","volume":"269","author":"Doody","year":"1995","journal-title":"Science"},{"key":"10.1053\/sonc.2003.50057_bib9","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.4049\/jimmunol.136.12.4470","article-title":"HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes","volume":"136","author":"Dorken","year":"1986","journal-title":"J Immunol"},{"issue":"suppl 1","key":"10.1053\/sonc.2003.50057_bib10","first-page":"36b","article-title":"Comparison of CD20 and CD22 expression by human peripheral blood B cells, tonsilar cells and lymphoma cell lines","volume":"98","author":"Kern","year":"2001","journal-title":"Blood"},{"key":"10.1053\/sonc.2003.50057_bib11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1084\/jem.173.1.137","article-title":"cDNA cloning of the B cell membrane protein CD22: A mediator of B-B cell interactions","volume":"173","author":"Wilson","year":"1991","journal-title":"J Exp Med"},{"key":"10.1053\/sonc.2003.50057_bib12","first-page":"4568","article-title":"Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma","volume":"49","author":"Pawlak-Byczkowska","year":"1989","journal-title":"Cancer Res"},{"key":"10.1053\/sonc.2003.50057_bib13","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1084\/jem.189.9.1513","article-title":"Identification of CD22 ligands on bone marrow sinusoidal endothelium implicated in CD22-dependent homing of recirculating B cells","volume":"189","author":"Nitschke","year":"1999","journal-title":"J Exp Med"},{"key":"10.1053\/sonc.2003.50057_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0960-9822(06)00057-1","article-title":"CD22 is a negative regulator of B-cell receptor signalling","volume":"7","author":"Nitschke","year":"1997","journal-title":"Curr Biol"},{"key":"10.1053\/sonc.2003.50057_bib15","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1126\/science.274.5288.798","article-title":"Hyperresponsive B cells in CD22-deficient mice","volume":"274","author":"O'Keefe","year":"1996","journal-title":"Science"},{"key":"10.1053\/sonc.2003.50057_bib16","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1006\/smim.1998.0121","article-title":"CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor","volume":"10","author":"Sato","year":"1998","journal-title":"Semin Immunol"},{"key":"10.1053\/sonc.2003.50057_bib17","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1084\/jem.20011783","article-title":"The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound","volume":"195","author":"Kelm","year":"2002","journal-title":"J Exp Med"},{"key":"10.1053\/sonc.2003.50057_bib18","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1084\/jem.20011796","article-title":"Sialic acid binding domains of CD22 are required for negative regulation of B cell receptor signaling","volume":"195","author":"Jin","year":"2002","journal-title":"J Exp Med"},{"key":"10.1053\/sonc.2003.50057_bib19","first-page":"4466","article-title":"Constitutive endocytosis and degradation of CD22 by human B cells","volume":"154","author":"Shan","year":"1995","journal-title":"J Immunol"},{"key":"10.1053\/sonc.2003.50057_bib20","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2003.50057_bib21","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1008389119525","article-title":"Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma","volume":"10","author":"Piro","year":"1999","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"10.1053\/sonc.2003.50057_bib22","first-page":"88a","article-title":"Final report on the safety and efficacy of retreatment with rituximab for patients with non-Hodgkin's lymphoma","volume":"94","author":"Davis","year":"1999","journal-title":"Blood"},{"key":"10.1053\/sonc.2003.50057_bib23","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/sonc.2003.50057_bib24","first-page":"73","article-title":"Immunophenotypic markers useful in the diagnosis and classification of hematopoietic neoplasms","author":"Knowles","year":"1992"},{"key":"10.1053\/sonc.2003.50057_bib25","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1074-7613(00)80339-8","article-title":"Tuning antigen receptor signaling by CD22: Integrating cues from antigens and the microenvironment","volume":"6","author":"Cyster","year":"1997","journal-title":"Immunity"},{"key":"10.1053\/sonc.2003.50057_bib26","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood.V94.4.1382","article-title":"CD22 cross-linking generates B-cell antigen receptor-independent signals that activate the JNK\/SAPK signaling cascade","volume":"94","author":"Tuscano","year":"1999","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1053\/sonc.2003.50057_bib27","first-page":"358a","article-title":"Phase I\/II trial of epratuzumab (humanized anti-CD22 antibody) in non-Hodgkin's lymphoma (NHL)","volume":"100","author":"Leonard","year":"2002","journal-title":"Blood"},{"key":"10.1053\/sonc.2003.50057_bib28","article-title":"Epratuzumab (anti-CD22) and rituximab (anti-CD20) combination immunotherapy for non-Hodgkin's lymphoma (NHL): Preliminary response data","author":"Leonard","year":"2002"},{"key":"10.1053\/sonc.2003.50057_bib29","series-title":"Zevalin (ibritumomab tiuxetan) [package insert]","year":"2002"},{"key":"10.1053\/sonc.2003.50057_bib30","first-page":"2228","article-title":"Non-Hodgkin's lymphomas","author":"Armitage","year":"2001"},{"key":"10.1053\/sonc.2003.50057_bib31","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ijc.2910560413","article-title":"Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2","volume":"56","author":"Shih","year":"1994","journal-title":"Int J Cancer"},{"key":"10.1053\/sonc.2003.50057_bib32","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood.V83.5.1390.1390","article-title":"Retention of B-cell-specific monoclonal antibodies by human lymphoma cells","volume":"83","author":"Press","year":"1994","journal-title":"Blood"},{"key":"10.1053\/sonc.2003.50057_bib33","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1517\/14712598.1.6.995","article-title":"Antibody targeted therapeutics for lymphoma: New focus on the CD22 antigen and RNA","volume":"1","author":"Newton","year":"2001","journal-title":"Exp Opin Biol Ther"},{"key":"10.1053\/sonc.2003.50057_bib34","first-page":"4052","article-title":"Phase I immunotoxin trial in patients with B-cell lymphoma","volume":"51","author":"Vitetta","year":"1991","journal-title":"Cancer Res"},{"key":"10.1053\/sonc.2003.50057_bib35","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1182\/blood.V85.12.3457.bloodjournal85123457","article-title":"Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: A phase I study","volume":"85","author":"Sausville","year":"1995","journal-title":"Blood"},{"key":"10.1053\/sonc.2003.50057_bib36","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/blood.V82.9.2624.2624","article-title":"A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy","volume":"82","author":"Amlot","year":"1993","journal-title":"Blood"},{"key":"10.1053\/sonc.2003.50057_bib37","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJM200107263450402","article-title":"Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia","volume":"345","author":"Kreitman","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/sonc.2003.50057_bib38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/10428190009060322","article-title":"Phase I\/II trial of multiple dose 131iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma","volume":"38","author":"Vose","year":"2000","journal-title":"Leuk Lymphoma"},{"issue":"suppl","key":"10.1053\/sonc.2003.50057_bib39","first-page":"3292s","article-title":"Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-\/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma","volume":"5","author":"Juweid","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1053\/sonc.2003.50057_bib40","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1200\/JCO.1991.9.4.548","article-title":"Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody","volume":"9","author":"Goldenberg","year":"1991","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775403700888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775403700888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T15:39:52Z","timestamp":1734017992000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775403700888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,4]]}},"alternative-id":["S0093775403700888"],"URL":"https:\/\/doi.org\/10.1053\/sonc.2003.50057","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2003,4]]}}}